[{"address1": "2533 South Coast Highway 101", "address2": "Suite 210", "city": "Cardiff", "state": "CA", "zip": "92007", "country": "United States", "phone": "858 400 8470", "website": "https://www.viracta.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.", "fullTimeEmployees": 40, "companyOfficers": [{"maxAge": 1, "name": "Mr. Mark Andrew Rothera", "age": 60, "title": "CEO, President & Director", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 959333, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Darrel P. Cohen M.D., Ph.D.", "age": 58, "title": "Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 576514, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Susan  Perrine M.D.", "title": "Scientific Founder and Consultant", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ronald J. Berenson M.D.", "age": 71, "title": "Co-Founder and Consultant", "yearBorn": 1952, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. George  Hillman", "title": "Co-Founder", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Thalia  Papayannopoulou M.D.", "title": "Co-Founder", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robert M. Williams Ph.D.", "age": 68, "title": "Co-Founder", "yearBorn": 1955, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Douglas V. Faller M.D., Ph.D.", "title": "Scientific Founder & Chairman of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael Eric Faerm", "age": 56, "title": "Chief Financial Officer", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ayman  El-Guindy", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.1609, "open": 0.165, "dayLow": 0.1613, "dayHigh": 0.1878, "regularMarketPreviousClose": 0.1609, "regularMarketOpen": 0.165, "regularMarketDayLow": 0.1613, "regularMarketDayHigh": 0.1878, "beta": 0.299, "forwardPE": -0.45948052, "volume": 2125655, "regularMarketVolume": 2125655, "averageVolume": 2457943, "averageVolume10days": 1934220, "averageDailyVolume10Day": 1934220, "bid": 0.1711, "ask": 0.1745, "bidSize": 100, "askSize": 100, "marketCap": 7030749, "fiftyTwoWeekLow": 0.13, "fiftyTwoWeekHigh": 1.31, "fiftyDayAverage": 0.1878, "twoHundredDayAverage": 0.4759, "currency": "USD", "enterpriseValue": 489971, "floatShares": 24783152, "sharesOutstanding": 39744200, "sharesShort": 2691476, "sharesShortPriorMonth": 1326060, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.0683, "heldPercentInsiders": 0.028380001, "heldPercentInstitutions": 0.50060004, "shortRatio": 1.85, "shortPercentOfFloat": 0.0868, "impliedSharesOutstanding": 39744200, "bookValue": 0.329, "priceToBook": 0.53769, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -45336000, "trailingEps": -1.1, "forwardEps": -0.61, "lastSplitFactor": "285:1000", "lastSplitDate": 1614211200, "enterpriseToEbitda": -0.01, "52WeekChange": -0.73770493, "SandP52WeekChange": 0.25443196, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "VIRX", "underlyingSymbol": "VIRX", "shortName": "Viracta Therapeutics, Inc.", "longName": "Viracta Therapeutics, Inc.", "firstTradeDateEpochUtc": 1127827800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "ed5f69f9-939f-3d89-84c4-600b43f665a9", "messageBoardId": "finmb_38720301", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.1769, "targetHighPrice": 3.0, "targetLowPrice": 3.0, "targetMeanPrice": 3.0, "targetMedianPrice": 3.0, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 30005000, "totalCashPerShare": 0.761, "ebitda": -49044000, "totalDebt": 18819000, "quickRatio": 1.047, "currentRatio": 1.084, "debtToEquity": 704.568, "returnOnAssets": -0.57197, "returnOnEquity": -2.0866702, "freeCashflow": -26057750, "operatingCashflow": -38238000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-02"}]